Skip to content

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Baby Bunting share price: is the stock a buy?

We unpack Baby Bunting's latest H1 results as well as look at what one top broker is currently saying about the stock.

Baby Bunting share price in focus Source: Bloomberg

Touting strong growth in a niche space, Baby Bunting (ASX: BBN) – a self-described one stop baby shop – has seen its share price rise more than 60% in the last 12-months.

Baby Bunting share price: interim results in focus

The release of the company’s interim results last week gave investors insight into how the company performed during the last six months of CY20 – and maybe most importantly: whether or not that ~60% run-up was justified.

Indeed, though the market first responded negatively – with the stock being bid down more than 10% following the H1 release – the share price has since stabilised.

Do you own Baby Bunting shares? You can hedge your downside risk by trading CFDs now.

Looking at these results, on the top-line, the company reported sales of $186.4 million – representing 8% growth on a pcp basis.

On the bottom-line, the company reported pro forma earnings (EBITDA) of $14.3 million (+21% on a pcp basis) and profits (NPAT) of $4.8 million. Margins also improved during the half, with gross profit margins hitting 36.9%.

The company further expects FY20 gross margins to come in even stronger: at 37.0%.

This margin outlook, said the company 'is an outcome of working with our supplier partners on range improvements, further improvements in trading terms, optimising supply chain opportunities and increases in direct import volumes.'

One key negative that stood out however as part of these results was commentary surrounding the potential impact of the Coronavirus.

Here it was noted that because 'Baby Bunting sources products, either directly or through distributors, from China. The effect on Baby Bunting arising from the coronavirus outbreak in China cannot yet be readily determined.'

The company did however reassure investor thats it had ‘sufficient’ stock on hand – suggesting there would be no inventory short-falls just yet.

The analyst view

In response to the H1, Citi reiterated their 'buy' rating and upgraded their share price target to $4.05 from $3.90 on BBN.

With Baby Bunting (ASX: BBN) currently trading at $3.58 per share, that price target would imply upside of ~13%.

The investment bank expects Baby Bunting to report FY20 sales of 403.5 million against earnings (Core NPAT) of $21.0 million.

However Citi analysts did flag that their NPAT guidance 'does not account for coronavirus disruption.'

'That said we see Baby Bunting as less exposed to this risk compared to other retailers given the company's elevated stock position following weaker than expected 1H20 sales combined with the fact that its suppliers also hold stock in Australia,’ Citi analysts also said.

Of the four brokers covering the stock, all of them rate Baby Bunting a ‘buy’, according to Bloomberg Data.

Practise trading Australian stocks with an IG demo account now.

This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.